ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused ‘out of an abundance of caution’
WEDNESDAY, Oct. 14, 2020 (HealthDay News) — Enrollment in a study testing an experimental antibody therapy against COVID-19 has been paused by independent monitors.
The study, ACTIV-3, was testing the use of a single antibody with the antiviral drug remdesivir. The antibody is being developed by Eli Lilly and the Canadian company AbCellera, the Associated Press reported. The study has been paused “out of an abundance of caution,” Lilly said Tuesday, but the company did not explain what prompted the decision.
The study is sponsored by the U.S. National Institute of Allergy and Infectious Diseases, which did not immediately comment, the AP reported.
After falling ill with COVID-19, President Donald Trump received an experimental two-antibody cocktail from Regeneron Pharmaceuticals Inc. Regeneron and Lilly are both seeking emergency use authorization from the FDA for their COVID-19 treatments while late-stage studies continue, the AP reported.
Health News Copyright © 2020 HealthDay. All rights reserved.